Does Humana Cover Belsomra (Suvorexant)?

How Humana Classifies Belsomra on Its Formulary

Humana places Belsomra on Tier 3 (non-preferred brand) in most commercial group and individual plans, which means the member pays a higher copay than generics but retains plan-rate pricing. On Humana Medicare Advantage (MA) Part D formularies, placement is more variable. Some MA plans slot Belsomra at Tier 4 with enhanced prior-authorization requirements, while a smaller number of plans exclude it from the formulary altogether.

Why the inconsistency? CMS allows Part D sponsors to design their own formulary tiers within federal guidelines, and Humana operates dozens of regional MA products. A 2023 analysis by the Kaiser Family Foundation found that Part D formulary exclusion lists grew by 19% between 2020 and 2023, disproportionately affecting branded drugs with available therapeutic alternatives. Belsomra falls into that category because generic zolpidem, eszopiclone, and low-dose doxepin serve the same indication at a fraction of the cost. The practical result: before filling Belsomra through Humana, verify formulary status through the plan's online drug-lookup tool or by calling the number on the back of the member ID card. Tier placement can shift at the start of each plan year.

Prior-Authorization Requirements for Belsomra on Humana

Nearly every Humana plan requires prior authorization (PA) before covering Belsomra. The PA process exists because the FDA-approved prescribing information limits suvorexant to insomnia characterized by difficulty with sleep onset or sleep maintenance, and Humana wants confirmation that the diagnosis and prescribing context meet those parameters.

Typical PA criteria include three elements. First, a confirmed diagnosis of chronic insomnia disorder by the prescribing clinician. Second, documentation that the patient has tried and failed (or has a documented contraindication to) at least one first-line generic hypnotic, usually zolpidem or eszopiclone. Third, a statement that the medication is being prescribed at FDA-approved doses (10 mg or 20 mg at bedtime). Some Humana MA plans add a fourth requirement: confirmation that the patient does not carry a concurrent diagnosis of narcolepsy, since suvorexant's orexin-blocking mechanism is pharmacologically related to the pathophysiology of narcolepsy and theoretically could worsen daytime sleepiness in those patients.

Turnaround time for standard PA decisions is 72 hours for commercial plans and up to 72 hours for Part D. An expedited (urgent) request can yield a decision within 24 hours if the prescriber indicates clinical urgency. The prescriber, not the patient, initiates the PA by submitting the request through Humana's provider portal or by fax.

Step-Therapy Rules: What Humana Expects You to Try First

Step therapy is the most common barrier to Belsomra access on Humana. The concept is straightforward: the plan requires evidence that a cheaper, clinically equivalent drug was tried before it will pay for the costlier one.

For insomnia, Humana's standard step-therapy protocol requires trial of at least one, and sometimes two, of the following generic agents: zolpidem (immediate or extended release), eszopiclone, low-dose doxepin (Silenor, now available generically), or ramelteon. If the patient experienced intolerable side effects, inadequate response after a reasonable trial (typically 7 to 14 days), or has a documented contraindication (such as a history of complex sleep behaviors with Z-drugs), the step-therapy requirement can be overridden.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment and lists suvorexant among several pharmacologic options when CBT-I is insufficient or unavailable [1]. That guideline does not rank one hypnotic above another, which gives prescribers clinical ammunition when arguing that suvorexant is a reasonable choice. A Cochrane review of orexin receptor antagonists for insomnia (Kishi et al., 2024) confirmed that suvorexant significantly improved subjective sleep onset latency and total sleep time compared with placebo across multiple trials [2].

What Belsomra Costs Through Humana vs. Cash Pay

Cost is often the deciding factor in whether a patient fights for insurance coverage or pays out of pocket. The manufacturer list price for Belsomra is approximately $340 for a 30-day supply. On a Humana Tier 3 plan, the member's copay typically ranges from $45 to $100 depending on the specific benefit design. For Tier 4 placement on an MA plan, coinsurance of 25% to 33% applies, which could mean $85 to $112 out of pocket per month.

Cash-pay pricing through discount pharmacy platforms has dropped significantly. GoodRx and similar aggregators frequently show suvorexant (generic, if available, or brand Belsomra) at $80 to $95 for 30 tablets. That means some patients on high-deductible Humana plans may actually pay less by using a discount card than by running the prescription through insurance before meeting their deductible.

Merck, the manufacturer, offers the Merck Patient Assistance Program for eligible uninsured or underinsured patients, and a separate Belsomra Savings Card for commercially insured patients. The savings card can reduce copays to as little as $15 per month, but it cannot be applied to Medicare, Medicaid, or Tricare prescriptions per federal anti-kickback statute requirements. Humana commercial members can typically stack the savings card on top of their plan benefit. Humana MA members cannot.

How to Appeal a Humana Denial of Belsomra

A denied PA is not the end of the road. Humana's internal appeals process offers at least two levels of review, and Medicare Advantage members have additional external appeal rights.

Step 1: Internal appeal. The prescriber (or the patient with prescriber support) submits a written appeal within 60 days of the denial notice (180 days for Part D). The appeal letter should include the clinical rationale for suvorexant specifically (not just "insomnia"), documentation of prior generic failures with dates, doses, and outcomes, and any supporting literature. Citing the phase 3 trial by Herring et al. (2012, Lancet Neurology, N=1,021) showing that suvorexant 20 mg reduced wake-after-sleep-onset by 22.4 minutes versus placebo at 3 months can strengthen the clinical case [3].

Step 2: Second-level internal appeal. If the first appeal is denied, Humana allows a second review by a physician reviewer who was not involved in the original decision. Include any new clinical documentation or a letter from the treating sleep specialist.

Step 3 (Medicare Advantage only): External review through MAXIMUS. If both internal appeals fail, MA members can request an independent review through MAXIMUS Federal Services, the CMS-contracted Independent Review Entity. MAXIMUS reviews are free to the member, and the IRE must issue a decision within 72 hours for expedited requests. According to CMS data from 2023, approximately 48% of Part D coverage determination appeals that reach the IRE level are decided in the enrollee's favor.

A letter of medical necessity from a board-certified sleep medicine physician carries more weight than one from a primary care provider at every level. If the patient has completed a sleep study (polysomnography or home sleep test) documenting the insomnia, include those results.

Clinical Evidence Supporting Suvorexant for Insomnia

Suvorexant works by blocking orexin receptors OX1R and OX2R in the hypothalamus, which suppresses the wake-promoting signal rather than broadly sedating the central nervous system. This mechanism distinguishes it from benzodiazepine receptor agonists (Z-drugs) and may explain its lower abuse liability and absence of next-day hangover effects at recommended doses.

The key registration trials enrolled over 3,000 adults with chronic insomnia. In the phase 3 study by Herring et al. published in Lancet Neurology (N=1,021), suvorexant 20 mg reduced subjective time to sleep onset by a mean of 9.4 minutes more than placebo and increased total sleep time by 16.1 minutes at month 1, with sustained effects through month 3 [3]. A separate 12-month safety study (N=521) found no evidence of rebound insomnia upon discontinuation and no signal for physical dependence [4].

The FDA approved suvorexant in August 2014 at doses of 10 mg and 20 mg, with the recommendation to start at 10 mg and increase only if the lower dose is tolerated but ineffective. The most common adverse effects in trials were somnolence (7% vs. 3% placebo), headache, and dizziness. The label carries a warning about next-morning impairment and advises against driving or other activities requiring full alertness until the patient knows how the drug affects them.

Dr. Andrew Krystal, a sleep researcher at UC San Francisco and contributor to the AASM guidelines, has noted: "Orexin antagonists represent a fundamentally different approach to insomnia pharmacotherapy. They target the wake drive rather than amplifying the sleep drive, which may offer advantages for patients who do poorly on GABA-ergic agents."

Belsomra vs. Other Insomnia Drugs on Humana Formularies

Understanding where Belsomra sits relative to competitors helps set expectations for coverage.

Generic zolpidem (immediate and extended release) sits on Tier 1 of virtually every Humana plan. No PA required. Copays run $3 to $10. Generic eszopiclone and low-dose doxepin are also Tier 1 or Tier 2 with minimal restrictions. Ramelteon, a melatonin receptor agonist, is generic and typically Tier 2.

Among newer branded DORAs, lemborexant (Dayvigo) occupies a similar Tier 3 position on Humana commercial plans, also requiring PA and step therapy. The choice between suvorexant and lemborexant often comes down to clinical preference, since the SUNRISE-1 trial (Rosenberg et al., 2019, JAMA Network Open, N=1,006) demonstrated lemborexant's efficacy in older adults specifically [5]. A prescriber making the case for one DORA over another should highlight the clinical rationale (e.g., patient age, comorbidities, prior DORA trial).

Quviviq (daridorexant), the newest DORA approved in 2022, may appear on Humana specialty tiers. Its phase 3 data (Mignot et al., Lancet Neurology, 2022, N=930) showed improvements in daytime functioning in addition to sleep parameters [6], which could serve as a differentiator in appeal letters if daytime impairment is a documented concern.

The bottom line: if cost and coverage simplicity are priorities, generic Z-drugs remain the path of least resistance on Humana. If the patient has a clinical reason to avoid GABA-ergic agents (history of complex sleep behaviors, substance use history, falls risk in older adults), the DORA class becomes medically necessary, and that distinction drives both the PA approval and the appeal strategy.

Tips for Getting Belsomra Covered by Humana on the First Try

Prescribers who build the PA submission with the following elements report higher first-pass approval rates. Document the insomnia diagnosis with duration (chronic is defined as 3 or more nights per week for 3 or more months per ICSD-3 criteria). List every prior pharmacologic and non-pharmacologic treatment with specific dates, doses, and reasons for discontinuation. State the clinical reason a DORA is preferred over a generic, such as fall risk, substance use history, or paradoxical reactions to Z-drugs. Include the AASM guideline citation supporting DORAs as an evidence-based option [1]. Request a specific dose (10 mg or 20 mg) that aligns with the FDA label.

Dr. Ilene Rosen, a past president of the AASM, has stated: "When insurers deny coverage of orexin antagonists, it is often because the prescriber's documentation did not clearly articulate why the generic alternatives were clinically inappropriate. The burden of specificity falls on us."

Patients can help by keeping a sleep diary for at least two weeks before the PA is submitted, documenting bedtime, wake time, number of awakenings, and any side effects from current medications. This contemporaneous record strengthens the case that current therapy is failing.